News
PERNIX PRESENTS DATA ON NOVEL EXTENDED RELEASE FORMULATION OF HYDROCODONE BITARTRATE AT PAINWEEK
Next-Generation Tablet Formulation Resists Physical Manipulation and Extraction of Hydrocodone In Vitro Data Supports Further Human Abuse Liability Studies LAS VEGAS, NV – September 9, 2015 (GLOBAL NEWSWIRE) – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a...
PERNIX RELEASES POSITIVE IN VITRO ABUSE DETERRENT DATA FOR THIRD GENERATION EXTENDED RELEASE HYDROCODONE ZX007
MORRISTOWN, N.J., July 27, 2015 (GLOBAL NEWSWIRE) – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced positive results from Category 1 (in vitro) abuse deterrence studies with ZX007, utilizing Altus Formulation’s...
Canadian Intellitab Patents
Montreal, Quebec, Canada Altus Formulation Inc. a Quebec – based drug formulation and development company, leveraging it’s patented drug delivery technologies to develop Safer to UseTM formulations for its partners and their patients today announced the issuance of...
ZX007, Altus’ INTELLITAB formulation of hydrocodone completes successful pharmacokinetic study
MORRISTOWN, N.J., May 05, 2015 (BUSINESS WIRE) -- Pernix Therapeutics Holdings, Inc. PTX, +0.94% a specialty pharmaceutical company, today announced the successful completion of a human pharmacokinetic equivalence study with ZX007, an innovative abuse deterrent tablet...
Altus Formulation Inc. Launches New European Business Initiative for INTELLITAB
Altus Formulation Inc. Montreal Monday February 2nd. 09:00 Altus Formulation Inc. is a Canadian Drug Formulation and Development Company, leveraging our patented drug delivery technologies to develop Safer to UseTM formulations for our partners and their patients....
Altus Announces New European Abuse Deterrent Technology Patents
Altus Formulation Inc. Montreal Altus Formulation Inc. a Quebec – based drug formulation and development company, leveraging it’s patented drug delivery technologies to develop Safer to UseTM formulations for its partners and their patients is pleased to announce the...
Notice of Allowance in the USA for its new Patent entitled sustained drug release compositions
Montreal Altus Formulation Inc. a Quebec – based drug formulation and development company, leveraging it’s patented drug delivery technology to develop safer formulations for its partners and their patients is pleased to announce the Notice of Allowance in the USA...
Zogenix Pursues Development of Abuse Deterrent Formulations of Zohydro ER with Altus Formulation
SAN DIEGO – November 1, 2013 - Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that it has entered into a Development and Option Agreement...